* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Dias nummer 1
Survey
Document related concepts
West Nile fever wikipedia , lookup
Marburg virus disease wikipedia , lookup
Swine influenza wikipedia , lookup
Henipavirus wikipedia , lookup
Cysticercosis wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Orthohantavirus wikipedia , lookup
Herpes simplex virus wikipedia , lookup
Whooping cough wikipedia , lookup
Influenza A virus wikipedia , lookup
Hepatitis B wikipedia , lookup
Neisseria meningitidis wikipedia , lookup
Anthrax vaccine adsorbed wikipedia , lookup
Transcript
CAF01 adjuvant increases the protection conferred by a commercially available influenza split vaccine in a ferret model C.J.M. Martel a*, T.H. Jensen a, L.P. Nielsen b, E.M. Agger b, M. Blixenkrone-Møller a, P. Andersen b, B. Aasted a a Department of Veterinary Disease Biology, Faculty of Life Sciences, University of Copenhagen, Stigbøjlen 7, DK-1870 Frederiksberg C, Denmark. b Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark. Abstract:The immunogenicity and protective efficacy of current preventive vaccines against influenza are considered suboptimal, and the development of novel effective influenza vaccination strategies is urgently needed. Commercially available trivalent split vaccines are known to elicit mainly a humoral immune response, whereas the induction of cell-mediated immune responses is negligible. Recently, a cationic liposomal adjuvant (CAF01, dimethyldioctadecylammonium/trehalose 6,6’-dibehenate) was developed. In the current study, we compared the immune response in ferrets vaccinated with a commercially available influenza split vaccine with the same vaccine mixed with the CAF01 adjuvant and furthermore used two recently circulating H1N1 viruses for the challenge of the animals. CAF01 improved the immunogenicity of the vaccine, increasing the influenzaspecific IgA and IgG levels as well as triggering cellular-mediated immunity, measured by flow cytometry as the production of interferon-gamma by lymphocytes. The adjuvant also enhanced the protection conferred by the vaccine, reducing the viral load measured in nasal washes by RT-PCR. The protection data obtained in the human relevant challenge model supports the potential of CAF01 in future influenza vaccines. Material and methods: •24 ferrets were immunized twice at two-weeks intervals, then challenged after a month of rest with 107 TCID of an homologous H1N1 virus. •Vaxigrip: 8 ferrets, 2 x 80 µl commercial vaccine •Vaccine + adjuvant group: 8 ferrets, 2 x 80 µl vaccine + 250 µl CAF01 •Control PBS group: 8 ferrets, 2 x 250 µl PBS •Viral titers in nasal washes were measured by RT-PCR, Influenza-specific antibodies were detected in serum via ELISA using homemade rabbit antiferret IgG, PBL positive for intracellular gamma-IFN staining after PMA stimulation were analyzed by flow cytometry. • In a similar experiment, 24 ferrets received various doses of influenza vaccine with or without CAF01 and then were challenged with a homologous H1N1 virus. Results and Conclusions B. HI titer ge e ha lle n of c ch of 11 0 ay ay D 0.15 g 0.15 g + CAF01 1.5 g 1.5 g + CAF01 15 g 15 g + CAF01 Mock-vaccinated ay 4 of ch al le ng e 1.010 5 D of 0 ay D st im af te r1 s ee k w Figure 2. Viral excretion A. Number of viral copies found in nasal washes of infected animals measured by quantitative RT-PCR. B. Number of copies in nasal washes of individual infected animals at peak replication day (day 3) C. Percentage of animals excreting the virus in their nasal washes during the challenge period (cumulative results of 3 similar experiments, for a total of 24 animals in each group). 2 Figure 1. Immune response to vaccine antigens. A. Serum IgG antibodies measured by IgG specific ELISA B. Hemagglutination inhibition assay C. Percentage of IFNg positive lymphocytes at week after 24 hours of stimulation in cell culture with a recombinant H1 hemagglutinin Number of viral copies D. 0 e C. al le ng 6 ch 5 of 4 1.010 6 3 3 D s ee k 2 w ee k w 2 2 Days after challenge inoculation 1.010 ay 1 *** 7 ge Days after challenge inoculation 0 1.010 8 ha lle n Day 3 *** * of c Day 2 11 10 0 ** 100 ay 10 1 50 1.010 9 0.15 g 0.15 g + CAF01 1.5 g 1.5 g + CAF01 15 g 15 g + CAF01 Mock-vaccinated D 10 2 *** 200 e 10 3 *** m Time post-immunization 10 4 100 300 al le ng 6 W ee k 4 W ee k 2 k W ee W ee k 0 0 10 5 Mock-vaccinated Vaxigrip Vaxigrip + CAF01 ch *** 1000 10 6 150 un iz at io n 2000 Mock-vaccinated Vaxigrip Vaxigrip + CAF01 10 7 al le ng un iz at io n e 0 D af te r1 *** 10 8 IgA titer in nasal washes 3000 Mock-vaccinated Vaxigrip Vaxigrip + CAF01 Animals excreting the virus (%) *** Number of viral copies 4000 HI titer m D. st im C. s B. af te r1 Day 3 after challenge inoculation ge 0 4 0 ha lle n 3 200 B. 0 st im Time post-immunization 2 400 50 A. Days after challenge inoculation * of c W 1 100 0.15 g 0.15 g + CAF01 1.5 g 1.5 g + CAF01 15 g 15 g + CAF01 Mock-vaccinated 600 D 5000 150 11 10 1 * *** *** 5000 ay 10 2 ** 200 *** 10000 0.15 g 0.15 g + CAF01 1.5 g 1.5 g + CAF01 15 g 15 g + CAF01 Mock-vaccinated D 10 3 * 10000 al le ng 10 4 Mock-vaccinated Vaxigrip Vaxigrip + CAF01 ch 6 10 5 10 0 ee k 4 W ee k 2 ee k W W ee k 0 *** 10 6 15000 of *** *** Mock-vaccinated Vaxigrip Vaxigrip + CAF01 *** *** *** ay 5000 4000 3000 2000 1000 0 10 7 2500 2000 1500 1000 500 *** un iz at io n *** 10 ** m Mock-vaccinated Vaxigrip Vaxigrip + CAF01 8 Number of viral copies *** Number of viral copies *** 100000 80000 60000 40000 20000 IgG titer in serum A. IgG titers in serum C. A. Figure 3. A/Brisbane/59/2007 study. A. Vaccine-specific serum IgG titers measured in serum by ELISA. B. Hemagglutination inhibition assay serum titers. C. Vaccinespecific IgA titers measured in nasal washes by ELISA. D. Number of viral copies found in nasal washes of individual infected animals at peak replication days (day 3 and 4), measured by quantitative RT-PCR. CAF01 enhances antibody and CMI responses of the split vaccine significant increase of vaccine-specific IgG antibodies titers in serum (fig 1A and 1 B) significant increase in the percentage of IFN-g positive lymphocytes (fig 1C) CAF01-adjuvanted split vaccine confers protection against H1N1 influenza challenge median number of viral copies 10 to 100-fold lower than vaccine only and the mock-vaccinated (fig 2A) CAF01 allows for a reduction in vaccine dose 0.15 µg dose of vaccine adjuvanted with CAF01 reduced the viral load to the same level as observed with the unadjuvanted 15 µg dose. With the 15 µg dose, the adjuvant led to a 100-fold reduction of the viral load compared to the same dose of vaccine without CAF01 (fig 3 D).